Given the unmet clinical need for the development of new therapeutics to treat post-MI heart failure, we investigated whether the effect of IGF-1/HGF therapy is also effective in the post-MI heart, in which cardiac adverse remodeling is already an active process. Here, HGF is linked to myocardial infarction.